Loading…
Employees: 104
Size C4 Therapeutics (CCCC) is a United States Health Care company (Biotechnology) with a market value of $381M, the 2897th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.10 on 6 Nov 2026.
Performance Over six months the shares gained 5.1%, against -32.9% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 2.3% over the last twelve months (peer median +2.8%); the operating margin is -288.3% (peer median -177.6%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 7.1× (6th cheapest of 16).
Capital Return on invested capital runs 176.2 points below its cost of capital (18.0% WACC).
Short interest Short interest is 34.7% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $35.0M | $35.9M | $35.6M | $20.8M | $31.1M |
| Revenue growth | — | +1% | +71% | -33% | — |
| Gross profit | $27.6M | $28.0M | $27.7M | $13.0M | $23.5M |
| EBITDA | -$93.6M | -$96.5M | -$109M | -$131M | -$122M |
| Net income | -$101M | -$105M | -$105M | -$132M | -$128M |
| Free cash flow | -$85.4M | -$99.3M | -$65.3M | -$109M | -$111M |
| Capital expenditure | $523,000 | $607,000 | $180,000 | $1.71M | $5.50M |
| Total debt | $56.9M | $60.0M | $65.8M | $71.0M | $87.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CCCC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.8% | -12.1% | 3rd highest of 20 |
| 6-month return | +5.1% | -32.9% | highest of 19 |
| Distance from 52-week high | -40.0% | -53.8% | 6th highest of 20 |
| Revenue growth (TTM) | +2.3% | +2.8% | 8th lowest of 16 |
| Operating margin | -288.3% | -177.6% | 8th lowest of 16 |
| EV / Sales | 5.3× | 7.1× | 6th cheapest of 16 |
| ROIC minus cost of capital | -176.2 pp | -17.7 pp | 3rd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |